Levulan^® PDT References

1. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14:275-292.

2. Levulan® Kerastick® Prescribing Information, DUSA Pharmaceuticals, Inc.® 

3. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol. 1998;134:207-214.

4. Svaasand LO, Wyss P, Wyss MT, et al. Desimetry model for photodynamic therapy with topically administered photosensitizers. Lasers Surg Med. 1996;18:139-149.

5. Nakaseko H, Kobayashi M, Akita Y, et al. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol. 003;148:122-127.

6. Data on file, DUSA Pharmaceuticals, Inc.®

7. Piacquadio DJ, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp. Arch Dermatol. 2004;140:41-46.

8. Tschen EH, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Brit J of Dermatol. 2006; 155:1262-1269.

9. Gupta G. et al. Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol. 2009; 161:221-227.

WEB 1431 Rev B